Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.28 Million EUR | -32.99% |
| 2022 | 39.21 Million EUR | 43.05% |
| 2021 | 27.41 Million EUR | 291.7% |
| 2020 | 6.99 Million EUR | -3.06% |
| 2019 | 7.22 Million EUR | 14.57% |
| 2018 | 6.3 Million EUR | 0.27% |
| 2017 | 6.28 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 20.47 Million EUR | 0.0% |
| 2024 Q1 | 20.47 Million EUR | -22.11% |
| 2023 Q3 | 26.28 Million EUR | -22.45% |
| 2023 FY | 26.28 Million EUR | -32.99% |
| 2023 Q4 | 26.28 Million EUR | 0.0% |
| 2023 Q2 | 33.89 Million EUR | 0.0% |
| 2023 Q1 | 33.89 Million EUR | -13.59% |
| 2022 Q4 | 39.21 Million EUR | 0.0% |
| 2022 Q3 | 39.21 Million EUR | -13.13% |
| 2022 Q2 | 45.14 Million EUR | 0.0% |
| 2022 Q1 | 45.14 Million EUR | 64.67% |
| 2022 FY | 39.21 Million EUR | 43.05% |
| 2021 FY | 27.41 Million EUR | 291.7% |
| 2021 Q2 | 31.21 Million EUR | 0.0% |
| 2021 Q3 | 28.31 Million EUR | -9.29% |
| 2021 Q4 | 27.41 Million EUR | -3.17% |
| 2021 Q1 | 31.21 Million EUR | 345.96% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 6.99 Million EUR | 0.0% |
| 2020 Q3 | 6.99 Million EUR | 0.0% |
| 2020 FY | 6.99 Million EUR | -3.06% |
| 2019 FY | 7.22 Million EUR | 14.57% |
| 2018 FY | 6.3 Million EUR | 0.27% |
| 2017 FY | 6.28 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -78.661% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 91.965% |
| Adocia SA | 24.95 Million EUR | -5.309% |
| Biophytis S.A. | 11.93 Million EUR | -120.183% |
| Advicenne S.A. | 12.4 Million EUR | -111.824% |
| genOway Société anonyme | 31.84 Million EUR | 17.465% |
| IntegraGen SA | 8 Million EUR | -228.498% |
| Medesis Pharma S.A. | 1.92 Million EUR | -1264.301% |
| Neovacs S.A. | 47.53 Million EUR | 44.711% |
| NFL Biosciences SA | 3.97 Million EUR | -561.885% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -76.23% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -601.431% |
| Sensorion SA | 46.49 Million EUR | 43.475% |
| Theranexus Société Anonyme | 7.23 Million EUR | -263.111% |
| TME Pharma N.V. | 2.49 Million EUR | -955.038% |
| Valbiotis SA | 33.24 Million EUR | 20.955% |
| TheraVet SA | 7.53 Million EUR | -248.823% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 25.495% |
| argenx SE | 4.11 Billion EUR | 99.361% |
| BioSenic S.A. | 9.55 Million EUR | -174.935% |
| Celyad Oncology SA | 16.28 Million EUR | -61.411% |
| DBV Technologies S.A. | 165.65 Million USD | 84.135% |
| Galapagos NV | 4.35 Billion EUR | 99.397% |
| Genfit S.A. | 173.87 Million EUR | 84.885% |
| GeNeuro SA | 6.31 Million EUR | -316.306% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 44.882% |
| Innate Pharma S.A. | 184.19 Million EUR | 85.732% |
| Inventiva S.A. | 69.13 Million EUR | 61.988% |
| MaaT Pharma SA | 42.93 Million EUR | 38.783% |
| MedinCell S.A. | 36.94 Million EUR | 28.87% |
| Nanobiotix S.A. | 93.89 Million EUR | 72.011% |
| Onward Medical N.V. | 43.62 Million EUR | 39.763% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 75.415% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 67.911% |
| Oxurion NV | 6.55 Million EUR | -301.237% |
| Pharming Group N.V. | 426.33 Million EUR | 93.836% |
| Poxel S.A. | 4.82 Million EUR | -444.91% |
| GenSight Biologics S.A. | 9.08 Million EUR | -189.215% |
| Transgene SA | 45.21 Million EUR | 41.878% |
| Financière de Tubize SA | 1.92 Billion EUR | 98.631% |
| UCB SA | 15.53 Billion EUR | 99.831% |
| Valneva SE | 469.39 Million EUR | 94.401% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 14.752% |